Study: Bone drug cuts risk of breast cancer relapse

Zometa, Novartis AG's bone-building drug, lowered the chances of breast cancer recurrence by 35% in premenopausal women with early-stage, hormone-sensitive breast cancer when combined with hormone therapy, a study of more than 1,800 patients found. The findings also showed that 9% of those who did not take Zometa in addition to hormone treatments either died or experienced a recurrence, compared with 6% of those who received the drug.

View Full Article in:

USA Today · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC